EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness of Buspirone in Alleviating Anxiety Symptoms in Patients with Depressive Disorder: A Multicenter Prospective Observational Study in Korea

Young Sup Woo iD, Won-Seok Choi iD, Jong-Hyun Jeong iD, Jonghun Lee iD, Do-Hoon Kim iD, Jong-Chul Yang iD, Se-Hoon Shim iD, Seung-Gul Kang iD, Young-Eun Jung iD, Won Kim iD, Chi-Un Pae iD, Won-Myong Bahk iD

Clinical Psychopharmacology and Neuroscience · 28.02.2025 · 23 (1) · 144-154

DOI: 10.9758/cpn.24.1255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Psychopharmacology and Neuroscience, online erschienen am 03.12.2024. Verfasst von Young Sup Woo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to investigate the effectiveness of buspirone as an adjunctive therapy for alleviating anxiety symptoms in patients with depressive disorders who are already taking antidepressants.

Methods

This was an open-label prospective multicenter non-interventional observational study conducted over 12 weeks. We enrolled 180 patients diagnosed with depressive disorders according to DSM-5 criteria and Hamilton Anxiety Rating Scale (HAMA) scores ≥ 18. Participants were already taking selective serotonin reuptake inhibitors or serotoninnorepinephrine reuptake inhibitors and were prescribed adjunctive buspirone. Efficacy was assessed using HAMA, Hamilton Depression Rating Scale (HAMD), Clinical Global Impression Scale-Improvement, Clinical Global Impression Scale-Severity, Sheehan Disability Scale (SDS), and WHO-5 Well-Being Index.

Results

The efficacy analysis included 161 patients. HAMA scores decreased significantly from 25.2 ± 6.7 at baseline to 15.4 ± 8.6 at 12 weeks (p < 0.001), whereas HAMD scores decreased from 19.4 ± 4.6 to 12.7 ± 5.7 (p < 0.001). WHO-5 and SDS scores showed significant improvements. The HAMA response rate was 39.1% and the remission rate was 13.7% at 12 weeks. Adverse drug reactions were reported in 3.7% of participants. Subgroup analyses showed no significant differences in treatment response based on buspirone dosage, baseline anxiety/depression severity, or benzodiazepine use.

Conclusion

Adjunctive buspirone therapy effectively improved anxiety symptoms in depressed patients taking antidepressants, regardless of baseline symptom severity or buspirone dosage. The treatment was well-tolerated with few adverse events. Future studies using a control group are needed.

Schlagwörter

Stichwörter der Autor:innen

AnxietyAnxious depressionBuspironeDepression

Autor:innen und Institutionen

  • Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Woo and Bahk Psychiatry Clinic, Seoul, Korea.
  • Department of Psychiatry, College of Medicine, Daegu Catholic University, Daegu, Korea.
  • Department of Psychiatry, Hallym University College of Medicine, Chuncheon, Korea.
  • Department of Psychiatry, Jeonbuk National University Medical School, Jeonju, Korea.
  • Department of Psychiatry, Soonchunhyang University Cheonan Hospital, College of Medicine, Soonchunhyang University, Cheonan, Korea.

ORCID-Profile: Young Sup Woo, Won-Seok Choi, Jong-Hyun Jeong, Jonghun Lee, Do-Hoon Kim, Jong-Chul Yang, Se-Hoon Shim, Seung-Gul Kang, Young-Eun Jung, Won Kim, Chi-Un Pae, Won-Myong Bahk

Zitieren

APA

Woo, Y. S., Choi, W. S., Jeong, J. H., Lee, J., Kim, D. H., Yang, J. C., Shim, S. H., Kang, S. G., Jung, Y. E., Kim, W., Pae, C. U., & Bahk, W. M. (2025). Effectiveness of Buspirone in Alleviating Anxiety Symptoms in Patients with Depressive Disorder: A Multicenter Prospective Observational Study in Korea. Clinical Psychopharmacology and Neuroscience, 23(1), 144-154. https://doi.org/10.9758/cpn.24.1255

Vancouver

Woo YS, Choi WS, Jeong JH, Lee J, Kim DH, Yang JC, et al. Effectiveness of Buspirone in Alleviating Anxiety Symptoms in Patients with Depressive Disorder: A Multicenter Prospective Observational Study in Korea. Clinical Psychopharmacology and Neuroscience. 2025;23(1):144-154. doi:10.9758/cpn.24.1255

BibTeX
@article{Woo2025,
  author = {Woo, Young Sup and Choi, Won-Seok and Jeong, Jong-Hyun and Lee, Jonghun and Kim, Do-Hoon and Yang, Jong-Chul and Shim, Se-Hoon and Kang, Seung-Gul and Jung, Young-Eun and Kim, Won and Pae, Chi-Un and Bahk, Won-Myong},
  title = {Effectiveness of Buspirone in Alleviating Anxiety Symptoms in Patients with Depressive Disorder: A Multicenter Prospective Observational Study in Korea},
  journal = {Clinical Psychopharmacology and Neuroscience},
  year = {2025},
  volume = {23},
  number = {1},
  pages = {144--154},
  doi = {10.9758/cpn.24.1255}
}
Kostenlos starten →